港股異動 | 華領醫藥-B(2552.HK)大漲超25% 聯合用藥臨牀試驗降糖效果顯著
格隆匯5月14日丨華領醫藥-B(2552.HK)大漲25.16%,報3.88港元,暫成交198萬港元,最新總市值40億港元。華領醫藥-B曾於4月27日宣佈,其全球首創雙效葡萄糖激酶調節劑dorzagliatin與恩格列淨組合研究成功,聯合用藥臨牀試驗降糖效果顯著。里昂近日發研報指,考慮到公司在臨牀試驗中的發展與預期基本一致,維持華領醫藥 dorzagliatin將在2022年產生收入的判斷,並基於現金流估值給予公司“買入”評級,目標價10.34港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.